Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check2 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2; removed the Back to Top element.SummaryDifference0.3%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.3%
- Check16 days agoChange DetectedThe web page has updated its facility name and location details, including specific drug information for Fruquintinib and sintilimab, while also removing previous location references and an older revision number.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.